Clinical Forum on (Re) Emerging Infectious Diseases

What's New

The Clinical Forum on (Re) Emerging Infectious Diseases successfully took place on Tuesday, 7 February 2023.
Registrations are still open!
Enduring Materials of the Mpox Clinical Forum 2022 are available to be revisited here.
To stay updated on the relevant developments, make sure you are signed up for our newsletter.

About this Program

Several countries in West and Central Africa have been reporting human Mpox infection since the 1970s but despite this, it has remained a neglected tropical infection that has been underfunded and under-researched. Sporadic exported cases outside of Africa have occurred several times over the years with very short chains of (mainly household or HCW) transmission beyond the index case. This situation changed in early May 2022 when the first cases of this global outbreak were reported to the WHO.

Since then, there have been near-simultaneous outbreaks in multiple countries which now affect at least all 6 WHO regions and at least 79 countries. The WHO declared the situation a PHIEC in late July. The outbreaks are occurring almost exclusively in sexually active gay and bisexual men who have sex with men (GBMSM). Infections in previously affected African countries are now accounting for 2% of the globally reported cases.

Similar to the Mpox outbreak, the WHO recently reported a surge of Ebola infections in Uganda (September 2022). There have been more than 100 confirmed cases of Ebola virus disease with a case fatality rate of almost 40%. With strict travel restrictions, the Uganda government was able to contain the outbreak.

There is an urgent need for education for clinicians in most countries who may never have seen or treated anyone with human Mpox infection and these re-emerging infectious diseases. There are many unanswered questions about transmission, asymptomatic disease, treatment, and vaccine efficacy for pre- and post-exposure prophylaxis, not to mention the evolution of a new phylogenetic classification nomenclature.

This program will aim to provide rapid education for those caring for people with human Mpox infection and these re-emerging infectious diseases from the perspective of clinicians previously and newly experienced with the disease.

This program is developed from the Mpox Clinical Forum in September 2022. The Mpox Clinical Forum in September 2022 was attended by 176 live participants from 58 countries, with 100% of them agreeing that this program increased their knowledge of Mpox, and 99% agreeing that the program was beneficial for the clinical management of people living with Mpox.

Program Directors

Jonathan Schapiro, MD

National Hemophilia Center, Sheba Medical Center, Israel

Daniel Kuritzkes, MD

Brigham and Women's Hospital / Harvard Medical School, United States

General Information

Who Should Attend?

- Healthcare providers involved in the care of people diagnosed with mpox;
- Infectious disease clinicians;
- Clinical virologists;
- Primary care physicians;
- Microbiologists; and
- Specialized nurses.

Meeting Objectives

This meeting aims to:
• Outline our current knowledge of the epidemiology of the recent viral outbreaks;
• Categorize the various clinical symptoms for case recognition/definition; and
• Reflect on the therapeutical options for treatment and prevention.

Practical Information

Certificate of Attendance

A certificate of attendance will be sent to participants after successfully completing the program and post-meeting survey.

Language

The official language of the meeting is English
Translation will not be provided.

Disclaimer

This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.

Liability and Insurance

By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.

Photographs, Audio, and Video Recording

Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.

Code of Conduct

All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.

Clinical Forum on (Re) Emerging Infectious Diseases

Related Enduring Materials

What's New

About this Program

Program Directors

Jonathan Schapiro, MD

Daniel Kuritzkes, MD

General Information

Practical Information

Program Directors

Jonathan Schapiro, MD

Daniel Kuritzkes, MD

Support Our Initiative

Become an Endorser

Endorsers

Previous Editions